Publications by authors named "Merhan Kamal Sayed"
Safety and Efficacy of Teplizumab for Treatment of Type One Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Anas Zakarya Nourelden Alaa Ahmed Elshanbary Loalo'a El-Sherif Amira Yasmine Benmelouka Hagar Ismail Rohim Merhan Kamal Sayed Mohamed Sayed Zaazouee
Endocr Metab Immune Disord Drug Targets
March 2022
Article Synopsis
- Teplizumab, a humanized anti-CD3 monoclonal antibody, may help reduce insulin dependency in type 1 diabetes mellitus (T1DM) patients, as shown in eight randomized clinical trials with 866 participants.
- The study found that patients taking teplizumab needed less insulin at multiple 6, 12, 18, and 24-month intervals, and displayed increased levels of C-peptide, indicating beta cell function.
- However, teplizumab did not significantly affect HbA1c levels and was associated with some adverse effects, including lymphopenia and skin disorders.